Algazi A, Tsai K, Bannavong D, et al. Clinical immune monitoring and biomarker data of pIL-12 monotherapy compared to pIL-12 with pembrolizumab in metastatic melanoma supports the rationale for combination therapy. SMR 2017, abstract FC05-3.
BO-112 plus pembrolizumab bij anti-PD-1-resistent gevorderd melanoom
aug 2025 | Dermato-oncologie, Immuuntherapie